• AI/ML Innovations' wholly owned subsidiary NeuralCloud signed an October 27, 2026, agreement with Etisense to integrate MaxYield into LASA software.
• The collaboration targets automated ECG labeling for preclinical research, initially in large-animal models, with potential expansion to small-animal models following validation.
• NeuralCloud will conduct validation at no charge to Etisense; further integration and online licensing require Etisense's written approval.
• The agreement is nonexclusive; NeuralCloud retains MaxYield intellectual property rights, while Etisense retains customer relationships and final review responsibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AI/ML Innovations Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610290730ACCESSWRNAPR_____1243442) on October 29, 2026, and is solely responsible for the information contained therein.